dc.contributor.author | Matutes, E | |
dc.date.accessioned | 2018-07-10T11:41:23Z | |
dc.date.issued | 2011-12 | |
dc.identifier | http://publications.icr.ac.uk/11317/ | |
dc.identifier.citation | JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (35), pp. 4696 - 4701 | |
dc.identifier.issn | 0732-183X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/2015 | |
dc.description.abstract | Purpose Adult T-cell leukemia/lymphoma (ATLL) is a mature (post-thymic) T-cell lymphoma associated with human T-lymphotropic virus type 1 infection. Survival in aggressive subtypes remains poor, and treatment resistance is frequent. Use of zidovudine (ZDV) and interferon alfa (IFN-alpha) has been associated with improved response rates in small studies and prolonged overall survival in leukemic ATLL subtypes in a recent meta-analysis. Patients and Methods We report the clinicopathologic characteristics, treatment, and outcome of 73 patients with aggressive ATLL (acute ATLL, 29; lymphoma ATLL, 44) diagnosed and treated in England between 1999 and 2009. The impact of ZDV/IFN-alpha on treatment response and survival was assessed. Results The overall response rate ranged from 49% with chemotherapy alone to 81% with combined first-line therapy (chemotherapy with concurrent/sequential ZDV/IFN-alpha). Median overall survival (OS) was 9 months: 7.5 months for acute ATLL and 10 months for lymphoma ATLL. Use of ZDV/IFN-alpha at any time prolonged survival in acute (P < .001) and lymphoma ATLL (P < .001) and was the sole factor associated with reduction in risk of death in aggressive ATLL (hazard ratio, 0.23; 95% CI, 0.09 to 0.60; P = .002). Combined first-line therapy prolonged median OS in acute (P = .0081) and lymphoma ATLL (P = .001) compared with chemotherapy alone. Conclusion These data support the use of low-dose ZDV/IFN-alpha with chemotherapy in first-line treatment of acute and lymphoma ATLL. | |
dc.format.extent | 4696 - 4701 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.subject | virus type-i leukemia-lymphoma arsenic trioxide japan combination progression nationwide features therapy disease | |
dc.title | Use of Zidovudine and Interferon Alfa With Chemotherapy Improves Survival in Both Acute and Lymphoma Subtypes of Adult T-Cell Leukemia/Lymphoma | |
dc.type | Journal Article | |
rioxxterms.licenseref.startdate | 2011-12 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | JOURNAL OF CLINICAL ONCOLOGY | |
pubs.issue | 35 | |
pubs.notes | ISI Document Delivery No.: 863CZ Times Cited: 0 Cited Reference Count: 29 Hodson, Andrew Crichton, Siobhan Montoto, Silvia Mir, Naheed Matutes, Estella Cwynarski, Kate Kumaran, Thurai Ardeshna, Kirit M. Pagliuca, Antonio Taylor, Graham P. Fields, Paul A. Amer soc clinical oncology Alexandria | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers) | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers) | |
pubs.volume | 29 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Molecular Haematology (including Cytogenetics Group and Cell Markers) | en_US |
dc.contributor.icrauthor | Matutes, Estella | |